xT CDx: FDA-APPROVED TUMOR + NORMAL ASSAY NOW AVAILABLE TO ORDER /// LEARN MORE xT CDx: FDA-APPROVED TUMOR + NORMAL ASSAY NOW AVAILABLE TO ORDER /// LEARN MORE
ORDER A TEST Log In Contact Us

DATA COLLABORATIONS

Accelerate therapy development with real-world multimodal data

Advance discovery, innovation, and increase the likelihood of trial success with real-world clinical and molecular data, including DNA, RNA and whole slide pathology images.

Contact Us

Supporting Key Development Milestones

  • UPCOMING WEBINAR:

    Discover novel biomarkers

    Leverage real-world multimodal data and bioinformatics expertise to identify disease subtypes and power discovery approaches to lead to novel therapeutic opportunities

    Read case study
  • UPCOMING WEBINAR:

    Generate and validate hypotheses

    Analyze your target of interest and identify the most appropriate patient population to evaluate for your therapy program

    Read case study
  • UPCOMING WEBINAR:

    Design late stage clinical trials

    Design trials, validate biomarker strategies, define optimal populations to study and assess execution feasibility.

    Read case study

Tempus lens

The full power of Tempus data at your fingertips

Harness the power of Tempus Lens, enhanced with Tempus One’s conversational AI capabilities, to analyze our extensive library of 7M+ de-identified research records. Uncover critical insights that can help accelerate innovation, and improve patient outcomes.

Explore now

How We Partner

Tempus offers flexible RWD solutions and services.

Data collaborations

Work with experienced Tempus scientists and biostatisticians to perform a scoped analysis based on your research objectives and criteria. Receive end-to-end support designing and executing retrospective data analyses.

Advanced analytics

Leverage Tempus Lens to conduct preliminary analyses and identify cohorts of interest, then migrate your records to Workspaces to generate additional insights in our cloud-based coding environment. Layer on AI agents for faster data curation and abstraction.

Top pharmaceutical and biotech companies trust Tempus to inform therapy development

WE’VE PARTNERED WITH

  • 95%

    of the top 20 pharma oncology companies

  • 200+

    biopharma companies

image description

We are very pleased to collaborate with Tempus to enhance our data-driven R&D strategy and glean critical insights that will deepen our understanding of complex tumor biology, enhance access to predictive preclinical models, and increase the probability of clinical success across our diverse pipeline.

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca

Learn more about our partnership with AstraZeneca

We are looking forward to working together now and in the future, as we continue to progress our current clinical candidates, test rational combinations, and bring forward new ones, with the goal of getting medicines to patients as quickly as possible.

Jorge DiMartino, M.D., Ph.D., Chief Medical Officer and Executive Vice President, Clinical Development, Kronos Bio

Learn more about our partnership with Kronos Bio

Our collaboration with Tempus provided valuable insights to prioritize disease indications based on target expression and its relationship with clinical outcomes. The breadth of the Tempus database allowed us to correlate response of many standard therapeutic regimens to target expression to support our clinical trial plans.

Jonghwa Won, Executive Vice President, Head of Early Development, ABL Bio

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer, Genmab

The Tempus Difference

  • ~7M

    de-identified research records to power scientific discovery

  • 1M+

    records with imaging data

  • 1M+

    records with matched clinical data linked with genomic information

  • 250K+

    records with whole transcriptomic profiles

  • 50x larger

    database than The Cancer Genome Atlas, the largest public genomic database

image description

News & Insights

view all RESOURCES
  • UPCOMING WEBINAR:

    Tempus One introduces new GenAI capabilities to query millions of unstructured documents for research and clinical care

    Read press release
  • UPCOMING WEBINAR:

    Industry experts discuss the integration of diverse omics data, from next-generation sequencing (NGS) to proteomics, and explore its transformative impact on the research landscape

    Watch replay
  • UPCOMING WEBINAR:

    Industry leaders highlight the importance of multimodal data, AI-driven diagnostics, and the necessity of innovative approaches to meet the challenges of oncology treatment

    Watch now
  • UPCOMING WEBINAR:

    The strategic collaboration will leverage Tempus’ large multimodal datasets to enhance BioNTech’s next-generation oncology pipeline Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collaboration with BioNTech SE (Nasdaq: BNTX, “BioNTech”)

    Read press release
  • UPCOMING WEBINAR:

    Hear from Tempus scientists on how biopharma organizations uncover critical insights within Tempus’ multimodal database using Lens to facilitate faster-time-to-insight and accelerate research and development

    Watch replay
  • UPCOMING WEBINAR:

    How AstraZeneca simplified its approach to TROPION-Lung01 and drove down time to launch

    Read case study

Other Solutions for Life Sciences

See how one of the industry’s largest, structured real-world datasets can support you throughout the therapy development process.